ArticleBrain and behavior2025
Impact of the COVID-19 Outbreak on the Incidence of Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes Associated Antibodies in Singapore.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests a potential association between COVID-19 and autoimmune encephalitis (AE). We aimed to evaluate the positivity rate of AE- and paraneoplastic neurological syndromes (PNS)-associated antibodies in relation to COVID-19.
methodsWe investigated the frequency and incidence of AE- and PNS-associated antibodies amongst clinical tests performed at the National Neuroscience Institute, Singapore, before and during the COVID-19 pandemic. Antibodies against surface-exposed antigens associated with AE were tested using cell-based assays; antibodies against intracellular antigens in PNS were detected by immunoblot and tissue-based assays.
resultsA total of 87 of 4347 samples and 29 of 3393 samples tested for AE- and PNS-associated antibodies, respectively, were positive. A spike in the incidence of AE-associated antibodies was observed in 2020 at 4.92 (95% CI, 3.05-7.53) per 1,000,000 person-years, coinciding with the first year of the COVID-19 "pandemic outbreak." The cumulative incidence in the "pre-pandemic" period from 2017 to 2019 was 2.44 (95% CI, 1.66-3.46) per 1,000,000 person-years (p = 0.034, vs. "pandemic outbreak"), and in the "mid to late pandemic" period from 2021 to 2023, this was 2.74 (95% CI, 1.91-3.82) per 1,000,000 person-years (p = 0.086, vs. "pandemic outbreak"). The incidence of PNS-associated antibodies was unaffected by the COVID-19 pandemic.
conclusionsThe increased incidence of AE-associated antibodies during the COVID-19 "pandemic outbreak" suggests a potential biological link. The subsequent decline in incidence in the "mid to late pandemic" period may be attributable to widespread vaccination and the emergence of new viral variants with less potential to induce autoimmunity. The incidence of PNS-associated antibodies was stable throughout, reinforcing its primary association with malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.